Taking Out OGA. The rationale behind small-molecule OGA inhibition is that these drugs will decrease tau hyperphosphorylation ...

An estimated 4,500 prescriptions have been filled in 2024 so far, Iwatsubo said. About 80 percent of patients have mild cognitive impairment, the rest have mild dementia. Most are in their 70s, and ...

“Bruce had a brilliant career in both academia and industry and left an indelible mark on the Alzheimer’s disease drug ...

The National Alzheimer’s Coordinating Center unites the collections of the neuropathology cores at 27 NIA-funded AD Research Centers into a single database. It contains records on 13,000 brains, 3,000 ...

Anti-amyloid antibodies lecanemab and donanemab are in clinical use now, but that does not mean research on them has stopped. At the Clinical Trials on Alzheimer’s Disease conference, held October ...

Dozens of rodents have been generated that model various aspects of ALS, like motor impairment or degeneration of motor neurons. No model recapitulates the human disease perfectly. By organizing ...

Unknown; predicted pathogenic in silico (CADD>20).

SORL1 knockout, knockin, and transgenic mice are now in the Research Models database. The database will be updated as more models become available.

To mark the 20th anniversary of Alzforum's launch in 1996, we have compiled a timeline reflecting the evolution of Alzheimer’s disease research, starting from Alois Alzheimer's public presentation of ...

Early onset familial Alzheimer disease (eFAD) is hereditary and marked by Alzheimer disease symptoms that appear at an unusually early age. Symptoms can start in a person's thirties, forties, and ...

Seeking ways to improve the safety of anti-amyloid antibodies, John Sims of Eli Lilly & Company presented a simple option to do so for donanemab at this year’s Clinical Trials on Alzheimer’s Disease ...